New Dual-Target antibody tested for safety in humans

NCT ID NCT07439263

Recruiting now Knowledge-focused Sponsor: Hinge Bio Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests the safety of a single dose of HB2198, an experimental antibody that binds to two immune cell targets (CD19 and CD20). About 32 healthy adults will receive either the drug or a placebo and be monitored for about two months. The goal is to see if the drug is safe and how the body processes it, before testing it in people with diseases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HB2198 (an experimental antibody that targets CD19 and CD20 proteins on immune cells)
What this could lead to: If safe, this could lead to further studies testing HB2198 for conditions involving B cells, such as autoimmune diseases or certain blood cancers.
What could go wrong: This is a very early Phase 1 trial in only 32 healthy people, so it cannot prove effectiveness. The antibody may cause side effects or fail in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER

Contacts and locations

Locations

Veritus Research
RECRUITING

Bayswater, Victoria, 3153, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.